Breaking News: Ocugen Inc. Submits Investigational New Drug Application to FDA for OCU200 Clinical Trial on Diabetic Macular Edema Treatment
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a… MALVERN, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it has submitted an…